

D M Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3329404/publications.pdf>

Version: 2024-02-01

45
papers

380
citations

840776

11
h-index

794594

19
g-index

45
all docs

45
docs citations

45
times ranked

732
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2015, 14, 291-295.	2.3	57
2	Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 104-114.	3.8	57
3	Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. <i>Annals of Oncology</i> , 2015, 26, 2102-2106.	1.2	37
4	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	1.9	29
5	Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer. <i>Oncotarget</i> , 2019, 10, 2947-2958.	1.8	27
6	Enfortumab Vedotin in urothelial cancer. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722098019.	2.0	24
7	Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature. <i>Oncology and Therapy</i> , 2021, 9, 21-39.	2.6	20
8	Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review. <i>Clinical Colorectal Cancer</i> , 2016, 15, e117-e123.	2.3	19
9	Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. <i>Cancer Medicine</i> , 2019, 8, 1584-1593.	2.8	18
10	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. <i>Current Oncology Reports</i> , 2020, 22, 14.	4.0	16
11	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e201-e210.	2.9	13
12	Transitioning to a New Normal in the Post-COVID Era. <i>Current Oncology Reports</i> , 2020, 22, 73.	4.0	10
13	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. <i>Oncology</i> , 2021, 99, 49-56.	1.9	9
14	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 356-365.	1.4	7
15	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. <i>Cancer Medicine</i> , 2020, 9, 3023-3032.	2.8	7
16	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	2.8	7
17	Do the American Society of Clinical Oncology (ASCO) Value Framework and the European Society of Medical Oncology (ESMO) Magnitude of Clinical Benefit Scale measure the same construct of clinical benefit?. <i>Journal of Clinical Oncology</i> , 2017, 35, 6509-6509.	1.6	3
18	Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1489-1496.	4.9	3

#	ARTICLE	IF	CITATIONS
19	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	1.1	2
20	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 79, 177-179.	1.9	2
21	Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer. <i>Current Oncology Reports</i> , 2021, 23, 36.	4.0	2
22	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 478-478.	1.6	2
23	Building a CTU Orientation Handbook iPad application for first-year residents. <i>Canadian Medical Education Journal</i> , 2019, 10, e111-e121.	0.4	2
24	The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210948.	3.2	2
25	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392.	0.4	1
26	Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4053-4053.	1.6	1
27	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-276.	1.6	1
28	Prognostic significance of malnutrition in metastatic esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 171-171.	1.6	1
29	Patterns of recurrence and outcomes after curative resection of locally advanced HER2-positive gastroesophageal cancer (HPGEC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 147-147.	1.6	1
30	Chemotherapy intensification for first-line treatment of poor-prognosis metastatic germ cell cancer is not yet ready for prime time. <i>Canadian Urological Association Journal</i> , 2019, 14, 48-49.	0.6	0
31	Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 699-699.	1.6	0
32	Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2017, 35, 126-126.	1.6	0
33	Outcomes for advanced HER2-positive gastroesophageal cancer by anatomical location: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2018, 36, 131-131.	1.6	0
34	Survival outcomes for de novo versus relapsed stage IV gastric and gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 148-148.	1.6	0
35	Management of metastatic gastric and esophageal cancer in older adults.. <i>Journal of Clinical Oncology</i> , 2018, 36, 163-163.	1.6	0
36	Comparison of bimodality versus trimodality therapy for esophageal or gastroesophageal junction (GEJ) cancer: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4066-4066.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.. Journal of Clinical Oncology, 2018, 36, 6619-6619.	1.6	0
38	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).. Journal of Clinical Oncology, 2019, 37, 162-162.	1.6	0
39	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.. Journal of Clinical Oncology, 2019, 37, 164-164.	1.6	0
40	Minimizing drug wastage (DW) and cost of cabazitaxel used to treat metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 6550-6550.	1.6	0
41	Patterns of disease, treatment, and outcomes of esophageal cancer arising within a previous radiation treatment field.. Journal of Clinical Oncology, 2020, 38, 328-328.	1.6	0
42	Clinicopathological features and treatment outcomes of young patients with gastric and esophageal cancers.. Journal of Clinical Oncology, 2020, 38, e16577-e16577.	1.6	0
43	Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.. Journal of Clinical Oncology, 2020, 38, 198-198.	1.6	0
44	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 58-58.	1.6	0
45	Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2022, 40, 562-562.	1.6	0